Research programme: oral insulin analogues - Merrion/Novo Nordisk

Drug Profile

Research programme: oral insulin analogues - Merrion/Novo Nordisk

Latest Information Update: 24 Dec 2010

Price : $50

At a glance

  • Originator Merrion Pharmaceuticals; Novo Nordisk
  • Class Insulins
  • Mechanism of Action Insulin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Diabetes mellitus
  • Research Unspecified

Most Recent Events

  • 22 Dec 2010 Early research in Undefined indication in Europe (PO)
  • 07 Dec 2009 NN 1952, the first candidate to emerge from the collaboration, enters clinical development
  • 24 Nov 2008 Preclinical trials in Diabetes mellitus in Europe (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top